Also known as T-cell growth factor and IL-2.
Phase 3 DeLLphi‑305: IMDELLTRA with durvalumab raised median OS to 21.1 vs 12.7 months, tripled PFS, and produced ~80% one‑year survival versus 53%.
FB102, a CD122 inhibitor, met the primary histology endpoint (Vh:Cd change; p=0.0176) versus placebo and showed aligned symptom and inflammatory benefits with no new safety signals.
Tarlatamab (IMDELLTRA) plus durvalumab showed statistically significant OS, PFS and ORR benefits versus durvalumab alone in Phase 3 DeLLphi‑305 for first‑line maintenance ES‑SCLC.
